Terfenadine can induce torsades de pointes in patients with liver cirrhosis due to impaired hepatic metabolism, indicating it should be avoided in this population.
Answers are grounded in this paper and cite their sources.
May warrant caution with terfenadine in cirrhosis; leaves open need for confirmatory studies before practice change.
A 65-year-old woman with liver cirrhosis complicated by hepatocellular carcinoma lost consciousness due to torsades de pointes with prolongation of the QT-interval after 10 days of treatment with terfenadine. Before terfenadine administration, she had shown neither symptoms of heart disease nor any electrocardiographic abnormalities. Serum electrolytes were all normal, although the Ca level was near the lower limit of the normal range. After the withdrawal of terfenadine, the QT-interval was normalized and the torsades de pointes disappeared. Since she had liver cirrhosis, the development of torsades de pointes was thought to be attributable to the impairment of hepatic metabolism by terfenadine.
No takes yet. Share an insight, caveat, or question.
Kamisako et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: